G protein-coupled receptors (GPCRs) form one of the largest drug target families, with 516 approved drugs targeting GPCRs. They play a central role in cellular signalling pathways, including neurotransmission, immune response and metabolic regulation, making them key targets for therapeutic intervention.

Currently approved drugs act on 121 GPCR targets, one-third of all non-sensory GPCRs. In 2025, 337 agents targeting 133 GPCRs, including 30 novel targets, were being investigated in clinical trials, with a shift towards a focus on metabolic and neurological disorders, as well as cancer.

However, GPCR research faces constraints due to the complexity of receptor signalling mechanisms and the challenge of maintaining data integrity, requiring increasingly advanced technologies and highly accurate assays.

Download this exclusive eBook from Eurofins DiscoverX to learn more about:   

  • GPCR biology and the development of new therapeutics  
  • Why you should measure signalling bias in your molecules  
  • Employing assay “volume control” to unveil efficacies in allosteric lead molecules 
  • How to unlock orphan GPCRs with a forward trafficking approach  
  • Accelerating development of GLP-1 & GLP-2 therapeutics 

Download your copy.